Clinical relevance of the HCV protease inhibitor-resistant mutant viral load assessed by ultra-deep pyrosequencing in treatment failure
详细信息 查看全文
- 作者：Sofiane Mohameda ; d ; Marc Bourliereb ; Souad Benalib ; Valerie Oulesb ; Paul Castellanib ; Hacè ; ne Khiria ; Claire Camusa ; Guillaume Penarandaa ; Laurent Chichee ; Dimitri Gonzalezc ; Chalom Sayadac ; Daniel Olived ; Philippe Halfona ; e ; philippe.halfon@alphabio.fr" class="auth_mail" title="E-mail the corresponding author
- 关键词：HCV ; hepatitis C virus ; GT ; genotype ; PIs ; protease inhibitors ; TLP ; telaprevir ; BOC ; boceprevir ; PEG-IFN ; pegylated-interferon ; RBV ; ribavirin ; SVR ; sustained virologic response ; DAAs ; direct-acting antivirals ; RAVs ; resistance associated variants ; UDPS ; ultra-deep pyrosequencing ; VF ; virological failure ; MID ; multiplex identifier ; AVA ; Amplicon Variant Analyzer ; GS Junior ; Genome Sequencer Junior ; BLNP ; variants analyser ; BLP ; baseline patients with persistence resistance variants ; VFNP ; virol
- 刊名：Journal of Clinical Virology
- 出版年：2016
- 出版时间：May 2016
- 年：2016
- 卷：78
- 期：Complete
- 页码：36-43
- 全文大小：1515 K
文摘
- •
A 0.5% detection threshold allows for a better characterization of the HCV viral population.
- •
UDPS demonstrated that the frequency of BOC or TLP RAVs persist for at least one year after therapeutic cessation.
- •
The relative mutant viral load must be considered prior to any PIs based re-treatment.